Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma

NCT01516593 is registered in ClinicalTrials.gov with Andres J. M. Ferreri as lead sponsor.

NCT NCT01516593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01516593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study on Safety and Activity of a Short Term Intensified Chemo-immunotherapy Combination in HIV-positive Patients Affected by Burkitt Lymphoma
Lead sponsor
Andres J. M. Ferreri
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
August 31, 2015
Enrollment
19 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt's lymphoma, hiv